Skip to main content
. 2021 Sep 28;61(4):195–208. doi: 10.1097/IIO.0000000000000364

Figure 1.

Figure 1

Key breakthroughs in the development of allotopic gene expression to treat mitochondrial defects. This timeline highlights the key breakthroughs in the development of allotopic gene therapies for the treatment of mitochondrial diseases. Leber hereditary optic neuropathy is the first mitochondrial disease for which a gene therapy was assessed in clinical trials and a market authorization was requested from the European Medicines Agency (EMA). Wallace et al.1; Roucou et al.27; Manfredi et al.29; Corral-Debrinski et al.33; Ellouze et al.34; ClinicalTrials.gov.35; GenSight Biologics website.36